Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i

Abstract Background Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are currently recommended by the National Comprehensive Cancer Network (NCCN) guidelines and the European Society for Medical Oncology (ESMO) guidelines as the first-line (1 L) treatment for...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Veronique Lambert, Sarah Kane, Belal Howidi, Bao-Ngoc Nguyen, David Chandiwana, Yan Wu, Michelle Edwards, Imtiaz A. Samjoo
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2024-05-01
سلاسل:	BMC Cancer
الموضوعات:	Breast cancer HR+/HER2- First-line CDK4/6i Real-world evidence Systematic literature review
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12885-024-12269-8
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!